Product Description
Exemestane is used to treat early and advanced breast cancer in women who have already stopped menstruating (postmenopausal). It is usually used in women who have already received a cancer medication called tamoxifen. Many breast cancer tumors grow in response to estrogen. (Sourced from: https://www.mayoclinic.org/drugs-supplements/exemestane-oral-route/side-effects/drg-20063757?p=1)
Mechanisms of Action: ARO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Peru, Poland, Portugal, Romania, Russia, Serbia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 21
Highest Development Phases
Phase 3: Breast Cancer
Phase 2: Bone Cancer|Granulosa Cell Tumor|Male Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Sarcoma|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LESS | P2 |
Active, not recruiting |
Breast Cancer |
2034-04-29 |
|
| TOL2506A-EXT | P3 |
Enrolling by invitation |
Breast Cancer |
2028-06-01 |
|
| DISCUSS | P2 |
Unknown Status |
Breast Cancer |
2028-05-15 |
|
| STUDY00026643 | P2 |
Not yet recruiting |
Ovarian Cancer|Prostate Cancer|Sarcoma|Breast Cancer|Pancreatic Cancer |
2027-12-31 |